Showing 6561-6570 of 8649 results for "".
- Aerie Pharmaceuticals Joins the ASCRS Foundation in Raising Funds to Provide Eye Care for the World’s Neediest Patientshttps://modernod.com/news/aerie-pharmaceuticals-joins-the-ascrs-foundation-in-raising-funds-to-provide-eye-care-for-the-worlds-neediest-patients/2480240/Aerie Pharmaceuticals announced that it is matching, $1 for $1, the first $25,000 donated by attendees at the 2018 ASCRS-ASOA Annual Meeting, being held in Washington DC, from April 13-17, to the ASCRS Foundation’s charitable eye care programs. “The ASCRS Foundation is amplifying a long tr
- Omeros Announces Upcoming Presentations of New Data on Omidria at the ASCRS Meetinghttps://modernod.com/news/omeros-announces-upcoming-presentations-of-new-data-on-omidria-at-the-ascrs-meeting/2480246/Omeros announced that the results of four studies directed to the benefits of Omidria across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The
- Omidria Added to Veterans Health Administration National Formularyhttps://modernod.com/news/omidria-added-to-veterans-health-administration-national-formulary/2480248/Omeros announced that the Veterans Administration (VA) has added Omidria (phenylephrine and ketorolac intraocular solution 1% / 0.3%) to the VA National Formulary. The VA National Formulary is a listing of drugs and supplies that must be available at all VA facilities for the benefit of U.
- Thomas W. Samuelson, MD, Named 2018 ASCRS Presidenthttps://modernod.com/news/thomas-w-samuelson-md-named-2018-ascrs-president/2480251/Thomas W. Samuelson, MD, a world-renowned ophthalmologist who specializes in the medical and surgical treatment of glaucoma and disorders of the anterior segment, will assume his role as president of the American Society of Cataract and Refractive Surgery (ASCRS) in April 2018. He currently serve
- EyePoint Pharmaceuticals Strengthens Global IP With Notices of Allowance for Two U.S. Patents Related to Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-strengthens-global-ip-with-notices-of-allowance-for-two-u-s-patents-related-to-dexycu/2480252/EyePoint Pharmaceuticals announced that the U.S. Patent and Trademark Office (USPTO) has issued Notices of Allowance for two patents covering Dexycu, the company’s FDA-approved long-acting intraocular product for the treatment of postoperative inflammation. The first patent (U.S. patent ap
- FDA Approves Marketing For First AI Device for Diabetic Retinopathy Detectionhttps://modernod.com/news/fda-permits-marketing-of-ai-based-device-to-detect-certain-diabetes-related-eye-problems/2480256/The FDA has permitted marketing for the first medical device to use artificial intelligence to detect greater than a mild level of diabetic retinopathy in adults who have diabetes. The device, called IDx-DR, is a software program that uses an artificial intelligence algorithm to analyze im
- Alcon to Present Robust Clinical Program, New Innovations at ASCRShttps://modernod.com/news/alcon-to-present-robust-clinical-program-new-innovations-at-ascrs/2480259/Alcon will showcase advancements in the cataract, glaucoma, and refractive spaces during the American Society of Cataract and Refractive Surgery (ASCRS) 2018 annual meeting, taking place April 13-17 in Washington, D.C. The company will leverage nearly 90 scientific abstract presentations, several
- Alcon Introduces Systane Complete Solution for Dry Eyehttps://modernod.com/news/alcon-introduces-systane-complete-solution-for-dry-eye/2480262/Alcon has introduced Systane Complete, a new formula designed to provide soothing relief for every major type of dry eye. The new product joins the Systane family of dry eye drops as a first-line treatment option for people who suffer from evaporative dry eye, aqueous tear deficient dry eye, or m
- SIFI Announces Approval of Mini Well Ready IOL in Singaporehttps://modernod.com/news/sifi-announces-approval-of-mini-well-ready-iol-in-singapore/2480263/Italian ophthalmic company SIFI has announced the approval of the Mini Well Ready IOL by Singapore’s Health Science’s Authority. Mini Well Ready is an innovative, aspherical, EDOF, progressive IOL designed for the surgical correction of presbyopia. “It is today increasingly rec
- Imprimis to Feature its Cyclosporine/Chondroitin Sulfate and Non-Opioid MKO Melt Formulations at the Upcoming ASCRS Meetinghttps://modernod.com/news/imprimis-to-feature-its-cyclosporine-chondroitin-sulfate-and-non-opioid-mko-melt-formulations-at-the-upcoming-ascrs-meeting/2480266/Imprimis Pharmaceuticals and its ophthalmology-focused ImprimisRx division announced its participation and related physician presentations at the 2018 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting to be held at the Walter E. Washington Convention Center in Washington,